[HTML][HTML] Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced EGFR …
Introduction Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
treatment of advanced EGFR-mutated NSCLC. Estimating differences in toxicity between …
Combination of chemotherapy and gefitinib as first‐line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: a randomized …
B Han, B Jin, T Chu, Y Niu, Y Dong, J Xu… - … journal of cancer, 2017 - Wiley Online Library
To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …
Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated …
JH Schiller, WL Akerley, W Brugger… - Journal of Clinical …, 2010 - ascopubs.org
LBA7502 Background: Orally administered ARQ197 is a selective, non-ATP competitive
inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and …
inhibitor of c-MET (MET), a receptor TK implicated in cancer cell migration, invasion, and …
[HTML][HTML] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British journal of …, 2014 - nature.com
Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …
MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a …
D Yue, S Xu, Q Wang, X Li, Y Shen, H Zhao… - The Lancet …, 2018 - thelancet.com
Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for …
T Mitsudomi, S Morita, Y Yatabe, S Negoro, I Okamoto… - 2012 - ascopubs.org
7521 Background: WJTOG3405 met its primary endpoint of progression free survival
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …